Speech-Language Pathologists in Ozark, AL Accepting Medicare

20 Speech-Language Pathologists found. Showing 1 - 20

Anna Carter, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

Ashton A Bergman, CFY-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336

Katelyn Marie Howard, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336

Ms. Anna Elizabeth Husfelt, M.S.CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

Patty Fenn, MS, CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

Hillary Leigh Sumblin Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336

Mrs. Caryl Crews Knolton, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

Cindy Carrell, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

Rita T Baker, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

Mikelyn Bolden, SPEECH LANUAGE PATHO Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 126 Hospital Ave, Ozark, AL 36360 Phone: 334-774-0750

Amanda Williams, M.E.D.-CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

Katharine Anne Nordin, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336

Mrs. Natalya Pavlovna Hoak, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

Sarah Lynn Joy Kowalczyk, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

Kirby Cosco, MA CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336

Natasha Nicole Dukes, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1880 S Union Ave Ste C, Ozark, AL 36360 Phone: 334-443-1043    Fax: 334-635-0348

Terri A Lee, SPEECH LANGUAGE PATH Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 126 Hospital Ave, Ozark, AL 36360 Phone: 334-774-0750

Mrs. Kristin Lindsey Deer, M.S., CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 123 S Painter Ave, Suite C, Ozark, AL 36360 Phone: 334-774-0370    Fax: 334-774-0732

Tara S Fowler, M.S. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

Emily Bass Eifert, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Sam Lisenby Rd, Ozark, AL 36360 Phone: 334-445-6336    Fax: 334-445-6363

News Archive

Enzyme called matriptase, when left to its own devices, can cause cance

Scientists at the National Institute of Dental and Craniofacial Research (NIDCR) and colleagues report in animal studies that a single, scissor-like enzyme called matriptase, when left to its own devices, can cause cancer.

Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.

Dining out is a recipe for unhealthy eating most of the time, study shows

The typical American adult gets one of every five calories from a restaurant, but eating out is a recipe for meals of poor nutritional quality in most cases, according to a new study by researchers at the Friedman School of Nutrition Science and Policy at Tufts University.

Nitrogen balance occurs with a precise 24-hour rhythm in mammals

Researchers at Case Western Reserve University School of Medicine demonstrated that nitrogen balance, the process of utilizing amino acids and disposing of their toxic byproducts, occurs with a precise 24-hour rhythm - also known as circadian rhythm - in mammals. Disruption of this cycle has a direct impact on survival of organisms, and may predispose one to life altering diseases including diabetes and cardiovascular disease.

Pfizer's Prevenar 13 granted European marketing authorization

The European Commission has granted Pfizer Inc. a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]). Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age. Invasive pneumococcal disease includes sepsis, meningitis, bacteremia, bacteremic pneumonia, and empyema.

Read more Medical News

› Verified 3 days ago